Page last updated: 2024-08-24

irinotecan and sb 202190

irinotecan has been researched along with sb 202190 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ait-Arsa, I; Askari, N; Bibeau, F; Boissière, F; Causse, A; Cortijo, C; Del Rio, M; Denis, V; Denouel, A; Gongora, C; Martineau, P; Marzi, L; Mollevi, C; Paillas, S; Pourquier, P; Vezzio-Vié, N1

Other Studies

1 other study(ies) available for irinotecan and sb 202190

ArticleYear
Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
    Cancer research, 2011, Feb-01, Volume: 71, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; HCT116 Cells; Humans; Imidazoles; Immunohistochemistry; Irinotecan; Isoenzymes; Leucovorin; MAP Kinase Signaling System; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Xenograft Model Antitumor Assays

2011